Sun Pharma enters patent litigation settlement with Celgene for launch of generic Revlimid

As per the terms of the settlement, Celgene will grant Sun Pharma a license to Celgene’s patents required to manufacture and sell certain limited quantities of generic lenalidomide capsules in the US beginning on a confidential date that is sometime after March 2022.

from Moneycontrol Business News https://ift.tt/3xEQ5Ef